Hess ( HES) upgraded at Credit Suisse from underperform to neutral. $68 price target. Net asset value is improving. HopFed Bancorp ( HFBC) upgraded to buy at TheStreet Ratings. Hewlett-Packard ( HPQ) upgraded at JP Morgan from underweight to neutral. $21 price target. Headline news will likely not get worse going forward. H&R Block ( HRB) downgraded at Morgan Stanley to underweight from equal-weight. $17 price target. IRS delays and stock run creates unattractive risk reward. Huntsman ( HUN) downgraded at Wells Fargo to market perform from overweight. $17-$19 price target. Valuation call. IBM ( IBM) downgraded at JP Morgan from overweight to neutral. $197 price target. Company has relatively lower growth potential. Incyte ( INCY) upgraded at Lazard from neutral to buy. $25 price target. Jakafi should see earlier adoption. Intuitive Surgical ( ISRG) upgraded at Lazard to buy, Lazard Capital Markets said. $600 price target. Stock is attractive, following a 10% pullback. JDS Uniphase ( JDSU) downgraded at Goldman from buy to neutral, Goldman Sachs said. Valuation call, based on a $14 price target. Louisiana-Pacific ( LPX) downgraded at DA Davidson from neutral to underperform, DA Davidson said. $18 price target. Recent move is strand board prices is likely not sustainable. Maxim ( MXIM) downgraded at Credit Suisse from outperform to neutral, Credit Suisse said. $31 price target. Expect significant deterioration in the handset market. Nucor ( NUE) upgraded at Keybanc from hold to buy, Keybanc said. Company is leveraged to lagging commercial construction markets. $56 price target. Old Dominion ( ODEL) downgraded at Deutsche from buy to hold, Deutsche Bank said. Valuation call, based on a $40 price target. Pharmacyclics ( PCYC) downgraded at Lazard to neutral. Company lacks near-term catalysts. Parexel ( PRXL) upgraded at Goldman from sell to neutral, Goldman Sachs said. $36 price target. Company can continue to expand margins over the coming quarters. Reliance Steel ( RS) downgraded at Keybanc from buy to hold. Estimates also cut, given a lower pricing environment. Sprint ( S) downgraded at UBS to neutral from buy, UBS said. $6 price target. 2013 outlook/operational challenges should keep shares range bound in 1H. Sprint downgraded at JP Morgan from overweight to neutral, JP Morgan said. $6 price target. Sales growth is decelerating.